AHA Urges Court to Block HRSA's 340B Rebate Program
The American Hospital Association and co-plaintiffs filed a reply brief Nov. 16 in U.S. District Court for the District of Maine seeking to preliminarily enjoin HRSA's 340B rebate program before it takes effect Jan. 1, in American Hospital Association v. Kennedy. The brief argues HHS failed to "fortify" the program as the court previously instructed and that it violates the Administrative Procedure Act's reasoned decision-making standard, citing an unexplained cost estimate of $537 million a year for covered entities and the exclusion of financing "float" costs calculated at $53.7 million annually for just 10 drugs. Plaintiffs also argue HHS fails to quantify the program's benefits and that the costs would force 340B hospitals to cut services, while disputing drugmakers' claims of financial harm by noting AbbVie's stock buybacks despite projected discount losses.